drugs, including biological products, the average or aggregate-- (i) costs of all clinical trials for each phase; (ii) percentage of success or failure at each phase of clinical trials; and (iii) public versus private funding levels of the trials for each phase; and (2) not later than 1 year after the date of enactment of this Act, submit a report to Congress on the results of such study, includin